Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk

Review

(2529) Views  (550) Full article downloads

Authors: Byron J Hoogwerf, Krupa B Doshi, Dima Diab

Published Date May 2008 Volume 2008:4(2) Pages 355 - 362

DOI: http://dx.doi.org/10.2147/VHRM.S1978

Byron J Hoogwerf, Krupa B Doshi, Dima Diab

Department of Endocrinology, Diabetes and Metabolism, Cleveland Clinic Foundation, Cleveland, USA

Abstract: Pramlintide is a synthetic version of the naturally occurring pancreatic peptide called amylin. Amylin and pramlintide have similar effects on lowering postprandial glucose, lowering postprandial glucagon and delaying gastric emptying. Pramlintide use in type 1 and insulin requiring type 2 diabetes mellitus (DM) is associated with modest reductions in HbA1c often accompanied by weight loss. Limited data show a neutral effect on blood pressure. Small studies suggest small reductions in LDL-cholesterol in type 2 DM and modest reductions in triglycerides in type 1 DM. Markers of oxidation are also reduced in conjunction with reductions in postprandial glucose. Nausea is the most common side effect. These data indicate that pramlintide has a role in glycemic control of both type 1 and type 2 DM. Pramlintide use is associated with favorable effects on weight, lipids and other biomarkers for atherosclerotic disease.

Keywords: pramlintide, glycemic control, diabetes mellitus